MedTrace Logo

Colchicine in Chronic Kidney Disease Patients

NCT06998862 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 744

Last updated 2025-05-31

No results posted yet for this study

Summary

The ColchiRen study is a phase 3, controlled, prospective, randomized, double-blind, and multicenter clinical trial. Its main objective is to demonstrate the benefit of low-dose colchicine treatment in secondary prevention of cardiovascular events in patients with moderate CKD. As a secondary objective, it aims to explore the potential beneficial anti-inflammatory effect on the progression of CKD.

Conditions

Interventions

DRUG

colchicine treatment in chronic kidney disease patients

colchicine treatment 0.5 mg/day

DRUG

placebo treatment

placebo treatment 1 pill/day

Sponsors & Collaborators

  • Hospital General Universitario Gregorio Marañon

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-12
Primary Completion
2028-12-30
Completion
2028-12-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06998862 on ClinicalTrials.gov